Cargando…

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study

OBJECTIVE: Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death in systemic sclerosis (SSc), facilitates earlier treatment. The objective of this study was to develop the first evidence-based detection algorithm for PAH in SSc. METHODS: In this cross-sectional, intern...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coghlan, J Gerry, Denton, Christopher P, Grünig, Ekkehard, Bonderman, Diana, Distler, Oliver, Khanna, Dinesh, Müller-Ladner, Ulf, Pope, Janet E, Vonk, Madelon C, Doelberg, Martin, Chadha-Boreham, Harbajan, Heinzl, Harald, Rosenberg, Daniel M, McLaughlin, Vallerie V, Seibold, James R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078756/ https://www.ncbi.nlm.nih.gov/pubmed/23687283 http://dx.doi.org/10.1136/annrheumdis-2013-203301

Ejemplares similares

Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study
por: Visovatti, Scott H, et al.
Publicado: (2014)

Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort
por: Bauer, Yasmina, et al.
Publicado: (2021)

Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries
por: Khanna, Dinesh, et al.
Publicado: (2021)

A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat
por: Remenova, Tatiana, et al.
Publicado: (2015)

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)
por: Pan, Zixuan, et al.
Publicado: (2019)

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
por: White, R. James, et al.
Publicado: (2019)

Risk stratification and medical therapy of pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations
por: Schwaiger, Johannes P., et al.
Publicado: (2013)

Pulmonary arterial hypertension: tailoring treatment to risk in the current era
por: Gaine, Sean, et al.
Publicado: (2017)

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
por: Simonneau, Gérald, et al.
Publicado: (2020)

Acute Right Ventricular Failure in the Setting of Acute Pulmonary Embolism or Chronic Pulmonary Hypertension: A Detailed Review of the Pathophysiology, Diagnosis, and Management
por: Matthews, Jennifer Cowger, et al.
Publicado: (2008)

Upfront Combination Therapy for Pulmonary Arterial Hypertension: Time to Be More Ambitious than AMBITION
por: Cascino, Thomas M., et al.
Publicado: (2021)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Patient perception of disease burden in diffuse cutaneous systemic sclerosis
por: Khanna, Dinesh, et al.
Publicado: (2019)

New horizons in pulmonary arterial hypertension management
por: McLaughlin, Vallerie, et al.
Publicado: (2014)

A paradigm shift in pulmonary arterial hypertension management
por: Rubin, Lewis J., et al.
Publicado: (2013)

Systemic sclerosis in the time of COVID-19
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2022)

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis
por: Distler, Oliver, et al.
Publicado: (2018)

Niemann-Pick type C Suspicion Index tool: analyses by age and association of manifestations
por: Wraith, James E., et al.
Publicado: (2013)

An overview of the 6th World Symposium on Pulmonary Hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Improving patient outcomes in pulmonary hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2015)

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
por: Galiè, Nazzareno, et al.
Publicado: (2021)

Future perspectives in pulmonary arterial hypertension
por: Simonneau, Gérald, et al.
Publicado: (2016)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
por: Coghlan, J. Gerry, et al.
Publicado: (2018)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019)

Imaging the heart in pulmonary hypertension: an update
por: Grünig, Ekkehard, et al.
Publicado: (2015)

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension
por: Coghlan, J. Gerry, et al.
Publicado: (2023)

Impact of patient characteristics and perceived barriers on referral to exercise rehabilitation among patients with pulmonary hypertension in the United States
por: Cascino, Thomas M., et al.
Publicado: (2020)

Is there still a role for cyclophosphamide in the treatment of systemic sclerosis?
por: Vonk, Madelon C
Publicado: (2020)

Elevated Pulmonary Pressure Noted on Echocardiogram: A Simplified Approach to Next Steps
por: Kanwar, Manreet K., et al.
Publicado: (2021)

Genetic screening for Niemann–Pick disease type C in adults with neurological and psychiatric symptoms: findings from the ZOOM study
por: Bauer, Peter, et al.
Publicado: (2013)

Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction: Study protocol for a randomized controlled trial
por: Mascherbauer, Julia, et al.
Publicado: (2016)

Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis
por: Denton, Christopher P, et al.
Publicado: (2022)

Increased CD39 Nucleotidase Activity on Microparticles from Patients with Idiopathic Pulmonary Arterial Hypertension
por: Visovatti, Scott H., et al.
Publicado: (2012)

Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial
por: Souza, Rogerio, et al.
Publicado: (2023)

On the detection of functionally coherent groups of protein domains with an extension to protein annotation
por: McLaughlin, William A, et al.
Publicado: (2007)

Pulmonary Hypertension: Types and Treatments
por: Rose-Jones, Lisa J, et al.
Publicado: (2015)

Stress Doppler echocardiography for early detection of systemic sclerosis-associated pulmonary arterial hypertension
por: Nagel, Christian, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lo0r8vpf25r7jtb4nrstf0pgr7